Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

If you are wheezing, coughing, or having extreme shortness of breath, you may be having an asthma attack.

APG808 resulted in a rapid and durable decrease from baseline in FeNO and pSTAT6 measurements throughout the 12 weeks.

In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic ...

Questions remain on whether there are links between patients with asthma and RA, including heterogeneity of disease.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...

In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...

The triple therapy inhaler delivers 3 active ingredients: beclomethasone dipropionate, an inhaled corticosteroid, formoterol fumarate, a long-acting beta-agonist, and glycopyrrolate, an ...

Please provide your email address to receive an email when new articles are posted on . Patients with mild asthma are still at risk for severe exacerbations, which can impact their quality of life.

Among patients with mild to moderate COVID-19, the asthma drug montelukast (Singulair) did not reduce duration of symptoms, results of the randomized controlled ACTIV-6 trial showed. After receiving ...